

Review Branch, Division of Extramural Research, National Inst of Dental & Craniofacial Research, 45 Center Dr., room 4AN32E, Bethesda, MD 20892, (301) 451-5096.

*Name of Committee:* National Institute of Dental and Craniofacial Research Special Emphasis Panel 05-57, Review of R01.

*Date:* May 19, 2005.

*Time:* 11 a.m. to 1 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Rebecca Roper, MS, MPH, Scientific Review Administrator, Scientific Review Branch, Division of Extramural Research, National Inst of Dental & Craniofacial Research, National Institutes of Health, 45 Center Dr., room 4AN32E, Bethesda, MD 20892, (301) 451-5096.

*Name of Committee:* National Institute of Dental and Craniofacial Research Special Emphasis Panel 05-69, Review of R21s(TM)/Pain).

*Date:* May 27, 2005.

*Time:* 3 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* H. George Hausch, PhD, Acting Director, 45 Center Drive, Natcher Building, Rm. 4AN44F, National Institutes of Health, Bethesda, MD 20892, (301) 594-2904, [george\\_hausch@nih.gov](mailto:george_hausch@nih.gov).

*Name of Committee:* National Institute of Dental and Craniofacial Research Special Emphasis Panel 05-72, Review RFA DE05-008.

*Date:* June 8, 2005.

*Time:* 8 a.m. to 6 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* BWI airport Marriott, 1743 West Nursery Road, Baltimore, MD 21240.

*Contact Person:* Lynn M. King, PhD, Scientific Review Administrator, Scientific Review Branch, 45 Center Dr., Rm 4AN-38K, National Institute of Dental & Craniofacial Research, National Institutes of Health, Bethesda, MD 20892-6402, (301) 594-5006.

*Name of Committee:* National Institute of Dental and Craniofacial Research Special Emphasis Panel 05-63, Review of U01.

*Date:* June 8, 2005.

*Time:* 11 a.m. to 1 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 45 Center Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Rebecca Roper, MS, MPH, Scientific Review Administrator, Scientific Review Branch Division of Extramural Research, National Inst. of Dental & Craniofacial Research, National Institutes of Health, 45 Center Dr., room 4AN32E, Bethesda, MD 20892, (301) 451-5096.

*Name of Committee:* National Institute of Dental and Craniofacial Research Special Emphasis Panel 05-67, Review of R21s (Materials).

*Date:* July 12, 2005.

*Time:* 10:30 a.m. to 12 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 45 Center Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Yujing Liu, MD, PhD, Scientific Review Administrator, National Institute of Dental & Craniofacial Res., 45 Center Drive, Natcher Building, Rm. 4AN38E, Bethesda, MD 20892, (301) 594-3169, [yujing\\_liu@nih.gov](mailto:yujing_liu@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS)

*Dated:* April 27, 2005.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05-8964 Filed 5-4-05; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Dental & Craniofacial Research; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* NIDCR Special Grants Review Committee 05-73, Review of R03s, Fs, Ks.

*Date:* June 16-17, 2005.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda, MD, Marriott Bethesda North Hotel and Conference Ctr, 5701 Marinelli Road, Bethesda, MD 20852.

*Contact Person:* Lynn Mertens King, PhD, Scientific Review Administrator, Scientific Review Branch, 45 Center Dr., Rm 4AN-32F, National Inst of Dental & Craniofacial Research, National Institutes of Health, Bethesda, MD 20892-6402, (301) 594-5006, [lynn.king@nih.gov](mailto:lynn.king@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and

Disorders Research, National Institutes of Health, HHS)

*Dated:* April 27, 2005.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05-8966 Filed 5-4-05; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive License: Cancer Diagnostic Based on Detecting Expression of Human Brother of Regulator of Imprinted Sites ("BORIS") and BORIS Antibodies

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), announces that the Department of Health and Human Services is contemplating the grant of an exclusive license to practice the inventions embodied in U.S. Provisional Patent Application Serial No. 60/611,789, entitled "Method of Detecting Cancer Based On Immune Reaction To BORIS" filed September 21, 2004 (E-241-2004/0-US-01); U.S. Provisional Patent Application Serial No. 60/358,889, entitled "Brother of The Regulator of Imprinted Sites (BORIS)" filed February 22, 2001 (E-227-2001/0-US-01); PCT Application No. PCT/US03/05186, entitled "Brother of The Regulator of Imprinted Sites (BORIS)" filed February 21, 2003 (E-227-2001/0-PCT-02); and U.S. Patent Application Serial No. 10/505,377, entitled "Brother of The Regulator of Imprinted Sites (BORIS)" filed August 19, 2004 (E-227-2001/-0-US-03), to NewLink Genetics Corporation, having a place of business in Ames, Iowa.

The prospective exclusive territory may be United States, Canada, Europe and Japan, and the field of use may be limited to manufacture and sale of Analyte Specific Reagents or FDA-approved in vitro diagnostics for cancer and cancer predisposition.

**DATES:** Only written comments and/or license applications which are received by the National Institutes of Health on or before July 5, 2005 will be considered.

**ADDRESSES:** Requests for copies of the patent and/or patent applications, inquiries, comments and other materials relating to the contemplated exclusive license should be directed to: Mojdeh

Bahar, J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804. Telephone: (301) 435-2950; Facsimile: (301) 402-0220; E-mail: [baharm@od.nih.gov](mailto:baharm@od.nih.gov).

**SUPPLEMENTARY INFORMATION:** The above-mentioned patent applications describe the human protein Brother of Regulator of Imprinted Sites ("BORIS"), and a method of detecting cancer by monitoring BORIS expression or by detecting anti-BORIS antibodies. Dr. Victor V. Lobanenkov and colleagues at the National Institute of Allergy and Infectious Diseases discovered BORIS and its potential application as a cancer diagnostic. BORIS is a paralog of CCCTC-binding factor ("CTCF"), a transcription factor that also functions in chromatin insulation. The amino acid sequences of BORIS and CTCF contain eleven conserved zinc fingers each of which binds to DNA. BORIS protein can be detected in cancer cells, and importantly, it is one of a few cancer-testis antigens that are immunogenic in humans.

BORIS resides in 20q13.2, a region that is commonly amplified in many human cancers. Normally, BORIS mRNA can be detected in testis, but not in other human tissues. However, BORIS mRNA is detectable in over one hundred cancer cell lines representing most of the major forms of human tumors and is also detectable in primary breast cancer tumor samples, but not in controls. BORIS protein is mis-expressed in cancer cell lines, and antibodies against BORIS have been detected in serum from patients with gliomas, lung, breast, or prostate cancers but not in serum from controls.

The correlation between cancer and BORIS expression indicates that detection of aberrantly expressed BORIS and/or anti-BORIS antibodies could serve as a method of screening or diagnosing cancer. In patients already known to have cancer, expression of BORIS could be monitored to measure a patient's response to a particular therapeutic regimen.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license in the field of use filed in response to this notice

will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 27, 2005.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 05-8967 Filed 5-4-05; 8:45 am]

**BILLING CODE 4140-01-P**

## INTERNATIONAL TRADE COMMISSION

[Investigations Nos. 751-TA-28-29]

### Certain Frozen Warmwater Shrimp and Prawns From India and Thailand

**AGENCY:** United States International Trade Commission.

**ACTION:** Institution and scheduling of review investigations concerning the Commission's affirmative determinations in investigations Nos. 731-TA-1066-1067 (Final), Certain frozen warmwater shrimp and prawns from India and Thailand.

**SUMMARY:** The Commission hereby gives notice that it has instituted investigations pursuant to section 751(b) of the Tariff Act of 1930 (19 U.S.C. 1675(b)) (the Act) to review its determinations in investigations Nos. 731-TA-1066-1067 (Final). The purpose of the investigations is to determine whether revocation of the antidumping duty orders on certain frozen warmwater shrimp and prawns from India and Thailand is likely to lead to continuation or recurrence of material injury to an industry in the United States. Certain frozen warmwater shrimp and prawns from India and Thailand are provided for in subheadings 0306.13.00 and 1605.20.10 Harmonized Tariff Schedule of the United States.

For further information concerning the conduct of these investigations, hearing procedures, and rules of general application, consult the Commission's Rules of Practice and Procedure, part 201, subparts A through E (19 CFR part 201), and part 207, subparts A, C, D, and E (19 CFR part 207).

**DATES:** Effective May 5, 2005.

**FOR FURTHER INFORMATION CONTACT:** Jim McClure (202-205-3191), Office of Investigations, U.S. International Trade Commission, 500 E Street, SW., Washington, DC 20436. Hearing-

impaired persons can obtain information on this matter by contacting the Commission's TDD terminal on 202-205-1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202-205-2000. General information concerning the Commission may also be obtained by accessing its Internet server (<http://www.usitc.gov>). The public record for these investigations may be viewed on the Commission's electronic docket (EDIS) at <http://edis.usitc.gov>.

## SUPPLEMENTARY INFORMATION:

**Background.**—On December 17, 2004, the Department of Commerce determined that imports of certain frozen and canned warmwater shrimp and prawns from India and Thailand are being sold in the United States at less than fair value (LTFV) within the meaning of section 731 of the Act (19 U.S.C. 1673) (69 FR 76916, 76918, December 23, 2004); and on January 6, 2005 the Commission determined, pursuant to section 735(b)(1) of the Act (19 U.S.C. 1673d(b)(1)), that an industry in the United States was materially injured by reason of imports of such LTFV merchandise. Accordingly, Commerce ordered that antidumping duties be imposed on such imports (70 FR 5143, February 1, 2005).

On January 6, 2005, when the Commission conducted its vote in these investigations, it stated that it was concerned about the possible impact of the December 26, 2004, tsunami on the shrimp industries of India and Thailand. The tsunami occurred prior to the closing of the record in these investigations on December 27, 2004. At the time the record closed, however, factual information as to any impact of the tsunami on the ability of producers in India or Thailand to produce and export shrimp was not available. On February 8, 2005, the Commission published a **Federal Register** notice (70 FR 6728) inviting comments from the public on whether changed circumstances exist sufficient to warrant the institution of changed circumstances reviews of the Commission's affirmative determinations concerning certain frozen warmwater shrimp and prawns from India and Thailand.

The Commission received 23 submissions in response to its **Federal Register** notice soliciting comments. Commenters that supported institution of changed circumstances reviews include Seafood Exporters Association of India, the Ministry of Commerce and Industry of India, the Department of Foreign Trade of the Royal Thai